The main objective of the present study was to compare the pharmacokinetics of vitamin D3 administered in 2 forms : a newly developed ibandronate 150-mg/vitamin D3 24,000-IU tablet ( DP-R206 , test drug ) and a stand-alone vitamin D3 24,000-IU tablet ( reference drug ) .